included a physician decision that involvement in the trial was not in the patient's best interest, known allergic reaction and / or severe allergic to arbidol, blood system dysfunction (platelet count \<100×109/l, hemoglobin level \<90g/l), severe liver dysfunction (total bilirubin level \>2 times the normal upper limit, aspartic aminotransferase and alanine aminotransferase levels \>3 times normal upper limit),severe renal dysfunction (serum creatinine \>1.5 times the upper limit of normal value, calculated creatinine clearance rate \<50 ml/min), treated with arbidol before admission, history of severe heart disease or clinically significant arrhythmia considered unsafe for the trial.

included a physician decision that involvement in the trial was not in the patient's best interest, known allergic reaction and / or severe allergic to arbidol, blood system dysfunction (platelet count \<100×109/l, hemoglobin level \<90g/l), severe liver dysfunction (total bilirubin level \>2 times the normal upper limit, aspartic aminotransferase and alanine aminotransferase levels \>3 times normal upper limit),severe renal dysfunction (serum creatinine \>1.5 times the upper limit of normal value, calculated creatinine clearance rate \<50 ml/min), treated with arbidol before admission, history of severe heart disease or clinically significant arrhythmia considered unsafe for the trial.

included a physician decision that involvement in the trial was not in the patient's best interest, known allergic reaction and / or severe allergic to arbidol, blood system dysfunction (platelet count <100×109/l, hemoglobin level <90g/l), severe liver dysfunction (total bilirubin level >2 times the normal upper limit, aspartic aminotransferase and alanine aminotransferase levels >3 times normal upper limit),severe renal dysfunction (serum creatinine >1.5 times the upper limit of normal value, calculated creatinine clearance rate <50 ml/min), treated with arbidol before admission, history of severe heart disease or clinically significant arrhythmia considered unsafe for the trial.

included a physician decision that involvement in the trial was not in the patient's best interest, known allergic reaction and / or severe allergic to arbidol, blood system dysfunction (platelet count <100×109/l, hemoglobin level <90g/l), severe liver dysfunction (total bilirubin level >2 times the normal upper limit, aspartic aminotransferase and alanine aminotransferase levels >3 times normal upper limit),severe renal dysfunction (serum creatinine >1.5 times the upper limit of normal value, calculated creatinine clearance rate <50 ml/min), treated with arbidol before admission, history of severe heart disease or clinically significant arrhythmia considered unsafe for the trial.

1. critical type: if one of the following conditions is met: a) respiratory failure occurs and mechanical ventilation is needed; b) shock occurred; c) patients with other organ failure need icu monitoring treatment. 2. severe type: if one of the following conditions is met: a) respiratory distress, rr ≥ 30 beats / min; b) in resting state, finger oxygen saturation (sao2) ≤ 93%; c) partial pressure of arterial oxygen (pao2) / concentration of oxygen inhaled (fio2)≤300mmhg） 3. those who have a history of allergy to this class of drugs and / or severe allergic constitution; 4. the results of laboratory tests are abnormal: a) hematological dysfunction is defined as: i) platelet (plt) count: <100 × 109 / l; ii) hemoglobin (hb) level <90g/l. b) abnormal liver function is defined as: i) level of total bilirubin(tbil) : >2 times upper limits of normal(uln); ii) the levels of aspartate aminotransferase (ast) and alanine transaminase (alt)：>3 times of uln. c) definition of renal dysfunction: serum creatinine>1.5 times of uln, or calculated creatinine clearance<50ml / min; d) definition of abnormal blood coagulation: international normalized ratio(inr) >1.5 times of uln, and the prothrombin time ((pt)) or activated partial thromboplastin time (aptt) is 1.5 times of uln, unless the subject is receiving anticoagulant therapy. 5. abidor was used before inclusion(tablets, capsules, granules). 6. women who are nursing or pregnant. 7. serum or urine pregnancy tests were positive for women of child-bearing age. 8. immunodeficient patient(patients with malignant tumors, organ or bone marrow transplant, hiv patient, those who took immunosuppressive drugs within 3 months before the screening test ). 9. with the following history of present illness: 1. neurological and neurodevelopmental disorders, these include diseases of the brain, spinal cord, peripheral nerves and muscles(such as cerebral palsy, epilepsy, stroke, mental retardation, moderate to severe developmental delay, muscular malnutrition or spinal cord injury ). 2. circulation system disease( congenital heart disease, congestive heart failure or coronary artery disease). 3. severe heart disease or a history of clinically significant arrhythmias that the researchers believe will affect participants' safety (according to the ecg or medical history). 10. other patients considered ineligible for this study were considered ineligible by the investigators

1. critical type: if one of the following conditions is met: a) respiratory failure occurs and mechanical ventilation is needed; b) shock occurred; c) patients with other organ failure need icu monitoring treatment. 2. severe type: if one of the following conditions is met: a) respiratory distress, rr ≥ 30 beats / min; b) in resting state, finger oxygen saturation (sao2) ≤ 93%; c) partial pressure of arterial oxygen (pao2) / concentration of oxygen inhaled (fio2)≤300mmhg） 3. those who have a history of allergy to this class of drugs and / or severe allergic constitution; 4. the results of laboratory tests are abnormal: a) hematological dysfunction is defined as: i) platelet (plt) count: <100 × 109 / l; ii) hemoglobin (hb) level <90g/l. b) abnormal liver function is defined as: i) level of total bilirubin(tbil) : >2 times upper limits of normal(uln); ii) the levels of aspartate aminotransferase (ast) and alanine transaminase (alt)：>3 times of uln. c) definition of renal dysfunction: serum creatinine>1.5 times of uln, or calculated creatinine clearance<50ml / min; d) definition of abnormal blood coagulation: international normalized ratio(inr) >1.5 times of uln, and the prothrombin time ((pt)) or activated partial thromboplastin time (aptt) is 1.5 times of uln, unless the subject is receiving anticoagulant therapy. 5. abidor was used before inclusion(tablets, capsules, granules). 6. women who are nursing or pregnant. 7. serum or urine pregnancy tests were positive for women of child-bearing age. 8. immunodeficient patient(patients with malignant tumors, organ or bone marrow transplant, hiv patient, those who took immunosuppressive drugs within 3 months before the screening test ). 9. with the following history of present illness: 1. neurological and neurodevelopmental disorders, these include diseases of the brain, spinal cord, peripheral nerves and muscles(such as cerebral palsy, epilepsy, stroke, mental retardation, moderate to severe developmental delay, muscular malnutrition or spinal cord injury ). 2. circulation system disease( congenital heart disease, congestive heart failure or coronary artery disease). 3. severe heart disease or a history of clinically significant arrhythmias that the researchers believe will affect participants' safety (according to the ecg or medical history). 10. other patients considered ineligible for this study were considered ineligible by the investigators